13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $1.9B | -$579M | 21.3% | -21.9% | — | $971M | $152M |
| 2024 | $2.6B | -$94M | 14.4% | -1.6% | — | $662M | $104M |
| 2023 | $2.0B | -$142M | 23.4% | -3.6% | — | $597M | $193M |
| 2022 | $1.4B | -$19M | 23.4% | 0.3% | — | $413M | $188M |
| 2021 | $908M | -$38M | 27.6% | -4.7% | — | $216M | $266M |
| 2020 | $925M | -$334M | 0.0% | -28.4% | — | $290M | $319M |
| 2019 | $846M | -$302M | 0.0% | -36.5% | -$78M | $294M | $101M |
| 2018 | $627M | -$53M | 0.0% | -7.6% | -$60M | $221M | $228M |
| 2017 | $435M | -$61M | 0.0% | -16.7% | -$56M | $121M | $238M |
| 2016 | $254M | -$160M | 0.0% | -93.4% | -$51M | $120M | $135M |
| 2015 | — | $332M | — | — | -$25M | $0 | $146M |
| 2014 | — | -$25M | — | — | $0 | — | $0 |
| 2013 | — | $20M | — | — | -$24M | — | $0 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $496M | -$27M | 16.9% | -2.1% | — | $973M | $142M |
| Dec '25 | $469M | -$429M | 20.7% | -87.1% | — | $971M | $152M |
| Sep '25 | $480M | -$21M | 20.8% | 0.2% | — | $1.1B | $117M |
| Jun '25 | $444M | -$20M | 22.6% | -0.3% | — | $821M | $151M |
| Mar '25 | $484M | -$65M | 21.2% | -0.3% | — | $819M | $247M |
| Dec '24 | $647M | -$23M | 11.7% | -2.9% | — | $662M | $104M |
| Sep '24 | $621M | -$23M | 13.0% | -2.6% | — | $600M | $97M |
| Jun '24 | $647M | $2M | 16.5% | 1.2% | — | $599M | $101M |
| Mar '24 | $640M | -$17M | 16.3% | -2.1% | — | $598M | $165M |
| Dec '23 | $556M | -$33M | 18.3% | -3.8% | — | $597M | $193M |
| Sep '23 | $511M | -$25M | 24.3% | -3.5% | — | $601M | $185M |
| Jun '23 | $469M | -$34M | 25.0% | -4.6% | — | $633M | $143M |
| Mar '23 | $428M | -$20M | 27.4% | -2.4% | — | $632M | $158M |
| Dec '22 | $382M | -$11M | 21.7% | -0.5% | — | $413M | $188M |
| Sep '22 | $353M | $2M | 24.4% | 3.7% | — | $412M | $157M |
| Jun '22 | $320M | -$5M | 22.0% | -1.4% | — | $283M | $193M |
| Mar '22 | $297M | -$5M | 26.0% | -0.9% | — | $283M | $210M |
| Dec '21 | $248M | -$6M | 0.0% | -4.9% | — | $216M | $266M |
| Sep '21 | $222M | -$13M | 0.0% | -3.0% | — | $238M | $252M |
| Jun '21 | $222M | -$9M | 0.0% | -3.5% | — | $233M | $207M |
How the market has priced EVH against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Evolent Health, Inc.'s revenue has grown 15.2% per year. These are computed facts, not advice.
As of FY2025, Evolent Health, Inc. reported $971M of total debt against $152M of cash; operating income covered interest expense -7.1×.
In FY2025, gross margin was 21.3%, operating margin -21.9%, and net margin -30.9%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.